| Patent ductus arteriosus: are current neonatal treatment options better or worse than no treatment at all? | |
| | |
MedLine Citation:
|
PMID: 22414883 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Although a moderate-sized patent ductus arteriosus (PDA) needs to be closed by the time a child is 1-2 years old, there is great uncertainty about whether it needs to be closed during the neonatal period. Although 95% of neonatologists believe that a moderate-sized PDA should be closed if it persists in infants (born before 28 weeks) who still require mechanical ventilation, the number of neonatologists who treat a PDA when it occurs in infants who do not require mechanical ventilation varies widely. Both the high likelihood of spontaneous ductus closure and the absence of randomized controlled trials, specifically addressing the risks and benefits of neonatal ductus closure, add to the current uncertainty. New information suggests that early pharmacologic treatment has several important short-term benefits for the preterm newborn. By contrast, ductus ligation, while eliminating the detrimental effects of a PDA on lung development, may create its own set of morbidities that counteract many of the benefits derived from ductus closure. |
| | |
Authors:
|
Ronald I Clyman; James Couto; Gail M Murphy |
Related Documents
:
|
18635733 - Effects of residential changes and time patterns on external-cause mortality in migrant... 3625613 - Convulsions in hypertensive, proteinuric primiparas more than 24 hours after delivery. ... 2760293 - Subcutaneous fat necrosis of the newborn: light, ultrastructural and histochemical micr... |
Publication Detail:
|
Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review |
Journal Detail:
|
Title: Seminars in perinatology Volume: 36 ISSN: 1558-075X ISO Abbreviation: Semin. Perinatol. Publication Date: 2012 Apr |
Date Detail:
|
Created Date: 2012-03-14 Completed Date: 2012-09-12 Revised Date: 2013-04-03 |
Medline Journal Info:
|
Nlm Unique ID: 7801132 Medline TA: Semin Perinatol Country: United States |
Other Details:
|
Languages: eng Pagination: 123-9 Citation Subset: IM |
Copyright Information:
|
Copyright © 2012 Elsevier Inc. All rights reserved. |
Affiliation:
|
Department of Pediatrics, Cardiovascular Research Institute, University of California, San Francisco, San Francisco, CA 94143, USA. clymanr@peds.ucsf.edu |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Cardiovascular Agents
/
therapeutic use* Ductus Arteriosus, Patent / drug therapy*, physiopathology, surgery, therapy Female Humans Indomethacin / therapeutic use* Infant, Newborn Infant, Premature, Diseases / drug therapy*, physiopathology, surgery Ligation Male Pregnancy Respiration, Artificial Unnecessary Procedures |
| Grant Support | |
ID/Acronym/Agency:
|
HL109199/HL/NHLBI NIH HHS; HL46691/HL/NHLBI NIH HHS; R01 HL046691-16/HL/NHLBI NIH HHS; R01 HL109199-01/HL/NHLBI NIH HHS |
| Chemical | |
Reg. No./Substance:
|
0/Cardiovascular Agents; 53-86-1/Indomethacin |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Diagnosis of the preterm patent ductus arteriosus: clinical signs, biomarkers, or ultrasound?
Next Document: Managing the patent ductus arteriosus in the premature neonate: a new look at what we thought we kne...